|Slideshows|October 4, 2021

The Cognitive Benefits of Matcha

A study compared matcha, a highly caffeinated green tea, to other sources of caffeine. Which had the greatest cognitive benefits?

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

AI-Driven Biomarker Discovery from Wearables in Neuropsychiatric Research

ByMark Gerstein, PhD

June 5th 2026

SYT-510 for Generalized Anxiety Disorder: Phase 2 Trial Dosing Initiated

ByLeah Kuntz

May 20th 2026

The Clinical Uses and Importance of Lifestyle Medicine in Psychiatry

ByFarah Abbas, BS,Asim A. Shah, MD

April 29th 2026

Prolactin Monitoring for Antipsychotics and the Impact of Stress

ByNilamadhab Kar, MD, DPM, DNB, FRCPsych

April 22nd 2026

EMP-01 for Social Anxiety Disorder Demonstrates Meaningful Improvements in Phase 2a Study

ByLeah Kuntz

April 22nd 2026

Latest CME

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

The Cognitive Benefits of Matcha

Related Content

AI-Driven Biomarker Discovery from Wearables in Neuropsychiatric Research

SYT-510 for Generalized Anxiety Disorder: Phase 2 Trial Dosing Initiated

The Clinical Uses and Importance of Lifestyle Medicine in Psychiatry

Prolactin Monitoring for Antipsychotics and the Impact of Stress

EMP-01 for Social Anxiety Disorder Demonstrates Meaningful Improvements in Phase 2a Study

Latest CME

Southern California Psychiatry Conference

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Monoamines: A Full House

Understanding the Complexities of Suicide Risk: A Conversation With Jill Harkavy-Friedman, PhD, and Elizabeth Ballard, PhD

Artificial Intelligence in Psychopharmacology: Promise and Pitfalls, With Roy Perlis, MD

Developing Next-Generation Psychedelic Treatments: Insights on Bretisilocin From AJ Cannon, MD

Next Generation Pharmacotherapies for Mood and Anxiety Disorders: An ASCP Poster Presentation Recap